Quantcast

Latest Non-Hodgkin lymphoma Stories

2014-08-19 23:02:37

Lack of Access and Financial Burden May Contribute to Increased Mortality, CPIC Researchers Find Fremont, CA (PRWEB) August 19, 2014 Despite advances in treatment, lymphoma patients residing in low socioeconomic status (SES) neighborhoods experienced significantly worse survival than patients living in high SES neighborhoods, researchers at the Cancer Prevention Institute of California (CPIC) have reported. Those who live in the poorest communities have a 34 percent greater risk of dying...

2014-08-06 16:28:52

Participants to Produce Strategic Roadmap for Accelerating Lymphoma Treatment Advances WASHINGTON, Aug. 6, 2014 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, will hold its first ASH Meeting on Lymphoma Biology, a meeting focused on furthering the treatment of lymphoma, August 10-13 in Colorado Springs, Colorado. More than 350 lymphoma experts from around the...

2014-07-28 16:26:36

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018https://www.reportbuyer.com/product/2225690/Global-Non-Hodgkin-Lymphoma-Therapeutics-Market-2014-2018.htmlAbout Non-Hodgkin Lymphoma (NHL) and its Diagnostic ProceduresNon-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die....

2014-07-21 04:21:39

SEATTLE, July 21, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI(®) (pixantrone). PIXUVRI in Israel is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL) who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has...

2014-07-17 12:29:31

-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments. As the leading fundraisers in the 2014 Man & Woman of the Year campaign, the 24(th) year for this prestigious program, these...

2014-07-14 12:55:18

The Lancet Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology. "The good news is that 5-year survival for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in...

2014-07-01 10:07:43

University of Pennsylvania School of Medicine Lack of clinical trial data, guidelines on HIV patients with cancer may contribute to health disparity HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal...

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-10 08:30:25

CAMBRIDGE, Mass., June 10, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that an abstract on EPZ-6438 has been accepted for oral presentation at the American Society of Hematology (ASH) Meeting on Lymphoma Biology, to be held August 10-13 in Colorado Springs, Colorado. The presentation will include findings characterizing the...

2014-06-09 14:34:42

Rockefeller University Press A new study in The Journal of Experimental Medicine reveals that a high-risk group of patients with follicular lymphoma could benefit from a novel drug combination. Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related